NYSE:MTNB

Matinas Biopharma Holdings Stock News

Healthcare > Biotechnology

Buy MTNB

*Your capital is at risk

$0.778

+0.0120 (+1.57%)

At Close: Jun 03, 2026

Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

07:30am, Wednesday, 11'th Oct 2023

BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid n

Matinas BioPharma to Present at Two Investment Conferences in October 2023

07:00am, Thursday, 28'th Sep 2023

BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molec

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

07:00am, Wednesday, 06'th Sep 2023

BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

08:00am, Wednesday, 26'th Jul 2023

BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intrace

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

07:30am, Thursday, 11'th May 2023

BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid na

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates

06:59pm, Wednesday, 10'th May 2023

Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

07:00am, Wednesday, 03'rd May 2023

BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery

7 Small-Cap Biotech Stocks with Massive Potential

06:36pm, Thursday, 27'th Apr 2023

While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappo

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript

08:26pm, Wednesday, 15'th Mar 2023

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Jody Cain - Investor Relations Jerry Jabbour - Chief Executive Officer Kei

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

07:00am, Wednesday, 08'th Mar 2023

BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delive

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by